Legacy Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $3.01M | Sell |
58,183
-3,027
| -5% | -$157K | 0.99% | 32 |
|
|
2021
Q4 | $3.61M | Buy |
61,210
+627
| +1% | +$31.1K | 1.17% | 24 |
|
|
2021
Q3 | $2.61M | Sell |
60,583
-1,250
| -2% | -$55.4K | 0.94% | 36 |
|
|
2021
Q2 | $2.42M | Buy |
61,833
+6,955
| +13% | +$270K | 0.87% | 38 |
|
|
2021
Q1 | $1.99M | Sell |
54,878
-8,374
| -13% | -$297K | 0.75% | 42 |
|
|
2020
Q4 | $2.33M | Sell |
63,252
-13,717
| -18% | -$503K | 0.91% | 37 |
|
|
2020
Q3 | $2.68M | Sell |
76,969
-1,217
| -2% | -$42.7K | 1.08% | 31 |
|
|
2020
Q2 | $2.43M | Sell |
78,186
-278
| -0.4% | -$9.45K | 1.04% | 33 |
|
|
2020
Q1 | $2.43M | Buy |
78,464
+1,071
| +1% | +$36.5K | 1.2% | 25 |
|
|
2019
Q4 | $2.88M | Buy |
77,393
+579
| +0.8% | +$20.6K | 1.16% | 30 |
|
|
2019
Q3 | $2.62M | Buy |
76,814
+446
| +0.6% | +$16.2K | 1.15% | 31 |
|
|
2019
Q2 | $3.14M | Buy |
76,368
+749
| +1% | +$29.7K | 1.39% | 23 |
|
|
2019
Q1 | $3.05M | Buy |
75,619
+500
| +0.7% | +$20K | 1.42% | 22 |
|
|
2018
Q4 | $3.11M | Buy |
75,119
+1,335
| +2% | +$55.4K | 1.65% | 18 |
|
|
2018
Q3 | $3.08M | Buy |
73,784
+1,919
| +3% | +$73.9K | 1.42% | 24 |
|
|
2018
Q2 | $2.47M | Sell |
71,865
-2,387
| -3% | -$81.6K | 1.21% | 28 |
|
|
2018
Q1 | $2.5M | Buy |
74,252
+750
| +1% | +$25.8K | 1.25% | 30 |
|
|
2017
Q4 | $2.53M | Buy |
73,502
+4,313
| +6% | +$147K | 1.25% | 33 |
|
|
2017
Q3 | $2.34M | Sell |
69,189
-38,281
| -36% | -$1.23M | 1.23% | 32 |
|
|
2017
Q2 | $3.42M | Buy |
107,470
+4,627
| +4% | +$146K | 1.85% | 20 |
|
|
2017
Q1 | $3.34M | Buy |
102,843
+4,079
| +4% | +$129K | 1.87% | 19 |
|
|
2016
Q4 | $3.04M | Buy |
98,764
+5,712
| +6% | +$174K | 1.84% | 17 |
|
|
2016
Q3 | $2.99M | Sell |
93,052
-1,033
| -1% | -$34.5K | 1.88% | 16 |
|
|
2016
Q2 | $3.14M | Sell |
94,085
-2,108
| -2% | -$67.3K | 1.96% | 14 |
|
|
2016
Q1 | $2.71M | Sell |
96,193
-738
| -0.8% | -$21.1K | 1.74% | 18 |
|
|
2015
Q4 | $2.97M | Buy |
96,931
+46,181
| +91% | +$1.45M | 1.91% | 14 |
|
|
2015
Q3 | $1.51M | Buy |
50,750
+12,437
| +32% | +$399K | 1.03% | 37 |
|
|
2015
Q2 | $1.22M | Buy |
38,313
+1,075
| +3% | +$35K | 0.79% | 46 |
|
|
2015
Q1 | $1.23M | Buy |
37,238
+4,427
| +13% | +$141K | 0.78% | 46 |
|
|
2014
Q4 | $970K | Buy |
32,811
+5,407
| +20% | +$155K | 0.62% | 57 |
|
|
2014
Q3 | $769K | Sell |
27,404
-422
| -2% | -$11.8K | 0.51% | 61 |
|
|
2014
Q2 | $784K | Buy |
27,826
+6,324
| +29% | +$180K | 0.51% | 61 |
|
|
2014
Q1 | $656K | Sell |
21,502
-843
| -4% | -$25.1K | 0.46% | 65 |
|
|
2013
Q4 | $650K | Sell |
22,345
-1,467
| -6% | -$42.7K | 0.46% | 63 |
|
|
2013
Q3 | $649K | Buy |
23,812
+118
| +0.5% | +$3.21K | 0.48% | 62 |
|
|
2013
Q2 | $630K | Buy |
+23,694
| New | +$655K | 0.48% | 60 |
|
Other funds holding PFE
Legacy Capital Partners's PFE Position: Q1 2022 in Review
Legacy Capital Partners reduced its Pfizer (PFE) stake by 4.9% in Q1 2022, selling an estimated $157K and leaving 58,183 shares worth $3.01M. The position accounts for 0.99% of the portfolio, ranked #32.
Legacy Capital Partners first reported a position in PFE in Q2 2013 and has held it in 36 quarters since. The position peaked at $3.61M in Q4 2021. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Legacy Capital Partners held 58,183 shares of Pfizer worth $3.01M as of Q1 2022.
- Legacy Capital Partners sold 3,027 Pfizer shares in Q1 2022, an estimated $157K.
- Pfizer made up 0.99% of Legacy Capital Partners's portfolio in Q1 2022, its #32 holding.
- Legacy Capital Partners first reported a position in Pfizer in Q2 2013 and has held it in 36 quarters since.
- Legacy Capital Partners's Pfizer position peaked at $3.61M in Q4 2021.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.